FDA Classifies Ventilator, Heart-Pump Recalls as Class I

FDA this week classified corrections to two unrelated critical-care devices as Class I recalls — the agency’s most serious category, reserved for situations where continued use without the recommended action could cause serious injury or death. One involves ResMed’s Astral ventilators; the other, Abiomed’s Impella heart-pump introducer kits. Neither is a product withdrawal. Both are corrections that leave the devices in service under revised instructions — which is precisely why hospitals need to know the details, not just the classification.

The ventilator: a component that can fail quietly

ResMed's issue sits inside the Astral 100 and Astral 150, portable ventilators used for both invasive and non-invasive life support. A supercapacitor on the main printed circuit board assembly can leak electrolyte over time. If enough leaks, the circuitry it sits on can be damaged, and the ventilator can enter a fail-safe state — a protective shutdown that also means ventilation stops if it happens mid-therapy. FDA's advice to clinicians is not to stop using an affected unit on the strength of the recall alone, but to confirm whether an installed main board is affected, keep backup ventilation equipment on hand and tested, and make sure everyone caring for the patient can respond immediately to a fail-safe alarm. Replacement circuit boards are in limited supply, so ResMed is prioritizing correction by patient risk rather than by first-in-line.

The heart pump: a clot risk, not a leak

Abiomed's action is narrower in scope but mechanically distinct from the introducer-kit recall FDA classified in June. That earlier action covered 14Fr and 23Fr introducers from a different product line, with a leakage defect at the sidearm, sheath cap, and hub score lines. This week's recall covers the 14Fr Low Profile Introducer Kit, product codes 1000434 and 1000435, which is compatible only with the Impella CP with SmartAssist 10th generation, product code 1000413 — so the pump itself is swept into the action along with the introducer. The failure mode is thrombus formation: a clot forming within the indwelling sheath lumen, or in the annular gap between the sheath's inner diameter and the catheter's outer diameter, during prolonged support. If the clot dislodges during ongoing support, manipulation, or removal, it can obstruct a peripheral vessel and cause ischemia requiring prompt clinical intervention.

• Abiomed recommended removing affected 14Fr Low Profile Introducer Kits and the compatible Impella CP with SmartAssist 10th generation pump sets from use or sale.
• J&J MedTech, which acquired Abiomed in 2022, says the 10th-generation device's limited distribution means the thrombus-risk correction touches six hospitals.
• ResMed asks providers to return an acknowledgment form confirming receipt of the correction notice and to distribute patient-facing materials without delay.
• Both corrections remain open and classified — not all affected units have been corrected yet in either case.

Why the pattern matters more than either recall alone

Two Class I recalls landing the same week is not, on its own, a trend — FDA classifies dozens of device corrections a year, and unrelated products colliding on the calendar is common. What is worth tracking is the second half of the pattern: Abiomed's Impella franchise has now drawn a Class I introducer-kit action twice in six weeks, for two different defects in two different products. For a quality team, that is a post-market surveillance signal independent of either individual recall's severity: repeated Class I findings in the same product family, even for unrelated failure modes, tend to draw closer FDA attention to the manufacturer's design controls and complaint-handling processes as a whole, not just to the specific parts named in the letters. The same logic runs through FDA's device user-fee negotiations, where the draft MDUFA VI recommendations lean on review consistency and deficiency-letter quality as much as on raw review-time goals.